Future Pain Drugs - A Report for 2002
Though strong competition from generics has
limited revenues in the pain management market, changing attitudes towards
pain treatment are revitalizing demand for new pain products and
administrative techniques.
The industry is addressing this demand by
offering new and innovative remedies, such as the fenatyl patch and Cox 2
inhibitors. Markets are forecast to experience strong growth over the
period dealt with in this report, as public perceptions about prescribed
narcotics change and as chronic pain is addressed more vigorously.
This report includes coverage of the
competitive market drivers and restraints, environment, revenue forecasts,
and much more.
* Detailed analysis of drugs in late stage
development, including clinical and marketing profiles
* In-depth comparative analysis of levels
of unmet need, R&D focus, drug class and pipeline products for pain
* Revenue forecasts for key drugs till 2005
This in-depth report examines the current
understanding of pain mechanisms from a basic and clinical perspective.
The management of pain, in particular chronic pain with established and
novel analgesics is discussed.
Future Pain Drugs examines trends in the
following pain types:
* Postoperative and preoperative pain
* Cancer pain
* Osteoarthritic pain
* Rheumatoid arthritic pain
* HIV and AIDS pain
* Neuropathy
* Post-herpetic neuralgia
* Low back pain
* Plus others...
Drugs in the pipeline for the management of
pain are discussed and related back to current understanding of the
neurobiology of pain. In particular the potential of COX-2 inhibitors,
NMDA receptor antagonists and gabapentin for the management of pain are
discussed.
- PRICING -
Individual report pricing - single user
copies of this report are available for only US$1595. Allow your whole
company to have access to this information for only the price of 5 copies.
Company-wide License (CD Rom and .pdf for company intranet use) for only
US$7995.
Size: 174 pages
Format: CD ROM
View
pdf brochure
To order - click
here!
